Fig. 4From: Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutationTTP (A) curves of EGFR/TP53 co-mutation patients divided by the presence of brain metastases; B, C, D OS curves of EGFR/TP53 co-mutation patients stratified by the presence of brain metastases (B), T790M status at progression (C) and EGFR mutation subtypes (D)Back to article page